No holdings information is available in our database.
Seeks to track, before fees and expenses, the LifeSci Biotechnology Clinical Trials Index. The Index is an equal weighted index that is designed to measure the equity market performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering that is in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development.
$18.83 +0.08 (0.43%)
As of 05/26/2022 16:00:00 EST IEX book CBOE book
2022 © Stock Market MBA, Inc.